SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total transaction of $43,400.00. Following the completion of the sale, the insider directly owned 213,387 shares of the company’s stock, valued at approximately $1,852,199.16. The trade was a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total transaction of $27,500.00.

SOPHiA GENETICS Trading Down 1.4%

Shares of SOPHiA GENETICS stock opened at $8.53 on Thursday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.85. The firm has a market capitalization of $715.58 million, a PE ratio of -7.42 and a beta of 0.96. The firm’s 50-day moving average price is $6.39 and its 200 day moving average price is $5.40.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The stock reached a new 12-month high, signaling strong recent momentum and investor interest. SOPHiA GENETICS Sets New 12-Month High
• Neutral Sentiment: Reported short interest was zero shares as of August 25, implying no measurable short-selling pressure. The data also showed no meaningful change from the prior period, limiting its usefulness as a trading signal.
• Negative Sentiment: CTO Abhimanyu Verma sold 5,000 shares for approximately $44,000 on August 24, reducing his position by 2.82%. Because the sale followed a pre-arranged Rule 10b5-1 plan, it may not reflect a current change in the executive’s outlook. SEC Form 4 filing
• Negative Sentiment: Director Kathy L. Hibbs sold 6,250 shares worth about $54,250 on August 25, decreasing her holdings by 5.71%. The sale adds to near-term insider-selling concerns but was also executed under a 10b5-1 plan. SEC Form 4 filing
• Negative Sentiment: Insider Philippe Menu sold 5,000 shares for approximately $43,400 on August 25, reducing his position by 2.29%. The transaction was pre-planned, which moderates—but does not eliminate—the potential negative signal from multiple insider sales. SEC Form 4 filing

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC raised its position in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the second quarter valued at $9,809,000. Principal Financial Group Inc. lifted its stake in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Archon Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.